Olema Pharmaceuticals, Inc. (OLMA)
7.11
-0.25
(-3.40%)
USD |
NASDAQ |
Oct 13, 13:16
Olema Pharmaceuticals Net Income (Quarterly) : -63.20M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -63.20M |
| March 31, 2026 | -53.09M |
| December 31, 2025 | -46.06M |
| September 30, 2025 | -42.22M |
| June 30, 2025 | -43.78M |
| March 31, 2025 | -30.39M |
| December 31, 2024 | -33.57M |
| September 30, 2024 | -34.56M |
| June 30, 2024 | -30.38M |
| March 31, 2024 | -30.97M |
| December 31, 2023 | -26.77M |
| September 30, 2023 | -21.50M |
| June 30, 2023 | -20.10M |
| Date | Value |
|---|---|
| March 31, 2023 | -28.29M |
| December 31, 2022 | -26.18M |
| September 30, 2022 | -22.72M |
| June 30, 2022 | -32.86M |
| March 31, 2022 | -23.03M |
| December 31, 2021 | -21.64M |
| September 30, 2021 | -17.71M |
| June 30, 2021 | -16.41M |
| March 31, 2021 | -15.34M |
| December 31, 2020 | -10.13M |
| September 30, 2020 | -7.844M |
| June 30, 2020 | -2.453M |
| March 31, 2020 | -1.693M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| SELLAS Life Sciences Group, Inc. | -9.605M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 63.20M |
| EPS Diluted (Quarterly) | -0.605 |
| Enterprise Value | 186.24M |
| Earnings Yield | -29.79% |
| Normalized Earnings Yield | -29.79 |